Plasma homovanillic acid in the prodromal phase of schizophrenia

Sumiyoshi, Tomiki; Kurachi, Masayoshi; Kurokawa, Kenzo; Yotsutsuji, Takashi; Uehara, Takashi; Itoh, Hiroko; Saitoh, Osamu

doi:10.1016/s0006-3223(99)00186-9

Cited by 31 publications

(18 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TH mRNA has been reported as increased in PBMC of both people with Sz and their siblings compared to controls [48] . Other changes such as elevation of plasma homovanillic acid (HVA), a breakdown product of DA, were noted among people with Sz [80] , people in the prodromal phase [81] and those with schizotypal personality disorder [82] but not in people with bipolar disorder [80] , suggesting some disorder specificity. In addition, protein of DA-and cAMP-regulated neuronal phosphoprotein of 32 kDa (DARPP-32), a critical downstream target of DRD1 and DRD5mediated signaling, was decreased in CD4 positive T lymphocytes and CD56 positive natural killer cells from people with Sz in comparison to control group [83] , indicating lymphocytes may therefore function as an easily accessible model to study the DA intracellular signaling in the cells of people with Sz.…”

Section: Monoamine Pathwaysmentioning

confidence: 99%

“…In addition, protein of DA-and cAMP-regulated neuronal phosphoprotein of 32 kDa (DARPP-32), a critical downstream target of DRD1 and DRD5mediated signaling, was decreased in CD4 positive T lymphocytes and CD56 positive natural killer cells from people with Sz in comparison to control group [83] , indicating lymphocytes may therefore function as an easily accessible model to study the DA intracellular signaling in the cells of people with Sz. Overall, some of the markers (i.e., TH and HVA) may prove to be markers for a high risk population, such as people with a family history of the disorder as they were not only dysregulated in people with Sz [48,80] but also in their siblings [48] as well as in prodromal individuals of Sz [81] or people with schizotypal personality disorder [82] . One caveat of using monoamine related molecules as biomarkers is that most of the antipsychotics would block their receptors [69] .…”

Section: Monoamine Pathwaysmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

140

108

View full text Add to dashboard Cite

Identifying biomarkers that can be used as diagnostics or predictors of treatment response (theranostics) in people with schizophrenia (Sz) will be an important step towards being able to provide personalized treatment. Findings from the studies in brain tissue have not yet been translated into biomarkers that are practical in clinical use because brain biopsies are not acceptable and neuroimaging techniques are expensive and the results are inconclusive. Thus, in recent years, there has been search for blood-based biomarkers for Sz as a valid alternative. Although there are some encouraging preliminary data to support the notion of peripheral biomarkers for Sz, it must be acknowledged that Sz is a complex and heterogeneous disorder which needs to be further dissected into subtype using biological based and clinical markers. The scope of this review is to critically examine published blood-based biomarker of Sz, focusing on possible uses for diagnosis, treatment response, or their relationship with schizophreniaassociated phenotype. We sorted the studies into six categories which include: (1) brain-derived neurotrophic factor; (2) inflammation and immune function; (3) neurochemistry; (4) oxidative stress response and metabolism; (5) epigenetics and microRNA; and (6) transcriptome and proteome studies. This review also summarized the molecules which have been conclusively reported as potential blood-based biomarkers for Sz in different blood cell types. Finally, we further discusses the pitfall of current blood-based studies and suggest that a prediction model-based, Sz specific, blood World Journal of Psychiatry W J P oriented study design as well as standardize blood collection conditions would be useful for Sz biomarker development.

show abstract

Section: Monoamine Pathwaysmentioning

confidence: 99%

Section: Monoamine Pathwaysmentioning

confidence: 99%

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Lai

Scarr

Udawela

et al. 2016

WJP

140

108

View full text Add to dashboard Cite

show abstract

“…Furthermore, HVA levels in cerebrospinal fluid were positively correlated with performance on the paired associates test, a test of verbal memory, in patients with Parkinson's disease (Mann et al 1983). We previously reported that pHVA levels are affected by acute mental stress in normal control subjects (Sumiyoshi et al 1998), and predict performance on a test of information processing in subjects in the prodromal phase of schizophrenia (Sumiyoshi et al 2000b). Thus, despite the fact that pHVA levels only partially reflect central dopaminergic function, they may reflect neural activity related to cognition, such as verbal memory.…”

Section: Introductionmentioning

confidence: 91%

“…Although the contribution of the central nervous system to peripheral pHVA concentrations has been reported to be no more than 35% (Kopin et al 1988;Maas et al 1988), pHVA levels have been suggested to be an indicator of several aspects of schizophrenia, including vulnerability to develop the illness (Siever et al 1991;Sumiyoshi et al 2000b). Indeed, baseline (pretreatment) pHVA levels have been shown to be influenced by polymorphism of the genes encoding the DA-D 3 receptor or tyrosine hydroxylase, the synthesizing enzyme of DA, in delusional disorder (Morimoto et al 2002).…”

Section: Introductionmentioning

confidence: 99%

Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia

et al. 2004

Self Cite

View full text Add to dashboard Cite

show abstract

“…Low pHVA levels have been associated with deficit states [8], whereas high baseline pHVA levels have been reported to be related with improvement of positive psychotic symptoms after treatment with antipsychotics [9]. Elevated pHVA levels have been shown to be correlated with severity of psychotic symptoms during acute relapse [10] and appeared to be present already in the prodromal phase of schizophrenia [11]. Furthermore, some authors have reported differences in pHVA between patients with first-episode psychosis (FEP) and those with relapsing or chronic psychoses, calling for further investigation [12].…”

Section: Introductionmentioning

confidence: 99%

Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders

Kerkhof

Fekkes²,

Heijden³

et al. 2015

Neuropsychobiology

View full text Add to dashboard Cite

Background: Psychosis spectrum disorders, especially schizophrenia, have been linked to disturbed dopaminergic activity in the brain. Plasma homovanillic acid (pHVA) levels partly represent dopaminergic metabolism in the central nervous system. In the present study associations between (changes in) pHVA levels, symptom severity and symptomatic improvement in patients with psychoses were investigated. Methods: From a total of 80 patients, 58 fulfilled all inclusion criteria and their symptom profile and severity were assessed by means of the Comprehensive Assessment of Symptoms and History (CASH), the Positive and Negative Syndrome Scale (PANSS) and the Clinical Global Impression Scale for Severity and Improvement (CGI-S/CGI-I) at baseline and after 6 weeks of antipsychotic treatment. After inclusion, all patients were prescribed first- or second-generation antipsychotics by their treating psychiatrist. A total of 12 patients had first-episode psychosis (FEP). At both time points, pHVA levels were measured. Subsequently, pHVA levels were compared with an age-matched control sample and changes in pHVA levels (ΔpHVA) after treatment were associated with clinical parameters. Results: Before analyses, data were scrutinized for possible confounders, particularly gender, smoking, medication status (including antipsychotic class), and recent drug use. The pHVA levels in patients were not different from those in controls. Treatment resulted in a significant decrease of all parameters. Symptomatic improvement as well as ΔpHVA was most pronounced in FEP patients. Conclusion: These findings show that patients with FEP have a more favourable outcome than non-FEP patients and that greater ΔpHVA also suggests that FEP patients still have the capacity to adjust dopaminergic neurotransmission.

show abstract

Plasma homovanillic acid in the prodromal phase of schizophrenia

Cited by 31 publications

References 31 publications

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics

Prediction of changes in memory performance by plasma homovanillic acid levels in clozapine-treated patients with schizophrenia

Relationship between Plasma Homovanillic Acid and Outcome in Patients with Psychosis Spectrum Disorders

Contact Info

Product

Resources

About